Santhera Pharmaceuticals Holding AG Logo

Santhera Pharmaceuticals Holding AG

Develops innovative medicines for rare neuromuscular and mitochondrial disorders.

SANN | SW

Overview

Corporate Details

ISIN(s):
CH1276028821
LEI:
54930035HAOFTTQH0U85
Country:
Switzerland
Address:
HOHENRAINSTRASSE 24, 4133 PRATTELN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for patients with rare diseases. The company targets conditions with high unmet medical needs, primarily in the area of rare neuromuscular and mitochondrial disorders. Santhera's mission is to provide treatment options for diseases that severely impact the lives of affected children and adults and currently have limited or no available therapies. Its development efforts include advanced treatments such as gene therapy for conditions like LAMA2-deficient congenital muscular dystrophy (CMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Santhera Pharmaceuticals Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Santhera Pharmaceuticals Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Santhera Pharmaceuticals Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-01-11 N/A Non-Executive member Buy None 42,600.00 CHF
2022-01-10 N/A Executive member Buy None 14,420.00 CHF
2022-01-05 N/A Executive member Buy None 37,000.00 CHF

Peer Companies

Chemical Works of Gedeon Richter Plc Logo
Develops and manufactures drugs for women's health, CNS, and cardiovascular diseases.
Hungary
RICHT
Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR

Talk to a Data Expert

Have a question? We'll get back to you promptly.